Ofer Gonen - 18 Mar 2026 Form 3 Insider Report for MediWound Ltd. (MDWD)

Role: Chief Executive Officer
Signature: /s/ Yaron Meyer, attorney-in-fact
Issuer symbol: MDWD
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 17:20:16 UTC
Previous filing: 03 Jan 2022
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gonen Ofer	Chief Executive Officer	C/O MEDIWOUND LTD., 42 HAYARKON STREET, YAVNE, ISRAEL	/s/ Yaron Meyer, attorney-in-fact	18 Mar 2026	0001796468

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MDWD	Ordinary shares						22,137	18 Mar 2026	Direct
holding	MDWD	Ordinary shares						35,714	18 Mar 2026	Direct	F1
holding	MDWD	Ordinary shares						11,784	18 Mar 2026	Direct	F2
holding	MDWD	Ordinary shares						8,500	18 Mar 2026	Direct	F3
holding	MDWD	Ordinary shares						8,900	18 Mar 2026	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MDWD	Series A Warrants							18 Mar 2026	Ordinary shares	8,168	$13.48	Direct
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	85,714	$13.14	Direct	F5
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	86,000	$11.88	Direct	F6
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	94,273	$12.73	Direct	F7
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	68,000	$18.54	Direct	F8
holding	MDWD	Stock Option (right to buy ordinary shares)							18 Mar 2026	Ordinary shares	71,000	$17.60	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F2	The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F3	The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F4	The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F5	The options reported in this row were granted to the Reporting Person on June 7, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F6	The options reported in this row were granted to the Reporting Person on May 31, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F7	The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F8	The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.
F9	The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.